Victory Capital Management Inc. Has $40.06 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Victory Capital Management Inc. boosted its stake in Natera, Inc. (NASDAQ:NTRA) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 315,543 shares of the medical research company’s stock after purchasing an additional 12,815 shares during the quarter. Victory Capital Management Inc. owned about 0.26% of Natera worth $40,058,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of NTRA. Itau Unibanco Holding S.A. acquired a new stake in Natera in the second quarter worth $28,000. Quarry LP grew its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC grew its holdings in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the period. Covestor Ltd grew its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the last quarter. Finally, Tobam acquired a new position in shares of Natera during the second quarter valued at about $74,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Down 3.3 %

NTRA opened at $146.06 on Friday. The company has a quick ratio of 4.01, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market cap of $19.28 billion, a price-to-earnings ratio of -82.99 and a beta of 1.53. Natera, Inc. has a twelve month low of $52.01 and a twelve month high of $167.79. The company’s 50-day moving average price is $127.38 and its two-hundred day moving average price is $115.46.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera’s revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) EPS. As a group, equities analysts expect that Natera, Inc. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of analyst reports. The Goldman Sachs Group lifted their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Morgan Stanley lifted their price objective on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, BTIG Research raised their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $137.65.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the sale, the chief executive officer now owns 185,034 shares of the company’s stock, valued at approximately $27,090,827.94. This represents a 2.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 2,212 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the sale, the director now directly owns 19,386 shares in the company, valued at $3,073,262.58. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,821 shares of company stock worth $4,776,878. 7.60% of the stock is owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.